<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00366483</url>
  </required_header>
  <id_info>
    <org_study_id>3098B1-130</org_study_id>
    <nct_id>NCT00366483</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Safety of Lecozotan SR in Healthy Young and Elderly Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Study of the Safety, Tolerability, and Pharmacokinetics of Lecozotan SR Administered Orally to Healthy Young and Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      To assess the safety, tolerability and pharmacokinetics of single and multiple ascending oral
      doses of lecozotan SR in healthy young and elderly subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of adverse events and adverse reactions will be calculated. The safety variables (vital signs, ECG parameters, and routine laboratory tests) and PK parameters will be measured throughout study period.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic analysis after single and multiple dosing</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Alzheimer Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lecozotan SR</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: -Young subjects: Men aged 18 to 45 years. -Elderly subjects: Men and
        women ≥ 65 years of age. -Body mass index in the range of 18 to 30 kg/m2 and body weight ≥
        50 kg. -Healthy as determined by the investigator.

        Exclusion Criteria: -History of any neuropsychiatric disorder. -History of drug or alcohol
        abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Trial Manager</last_name>
    <role>Principal Investigator</role>
    <affiliation>For France, infomedfrance@wyeth.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2006</study_first_submitted>
  <study_first_submitted_qc>August 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2006</study_first_posted>
  <last_update_submitted>March 15, 2007</last_update_submitted>
  <last_update_submitted_qc>March 15, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2007</last_update_posted>
  <keyword>healthy young volunteers</keyword>
  <keyword>healthy elderly volunteers</keyword>
  <keyword>Alzheimer's disease</keyword>
  <keyword>5HT1A antagonist</keyword>
  <keyword>Health</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

